ValuEngine upgraded shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) from a hold rating to a buy rating in a report released on Sunday.
A number of other analysts also recently commented on the stock. BidaskClub downgraded shares of Aquinox Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, April 10th. Zacks Investment Research downgraded shares of Aquinox Pharmaceuticals from a hold rating to a sell rating in a report on Friday, March 16th. Finally, Needham & Company LLC restated a buy rating and set a $25.00 price target on shares of Aquinox Pharmaceuticals in a report on Tuesday, May 8th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $22.80.
AQXP stock opened at $15.64 on Friday. The stock has a market capitalization of $369.55 million, a price-to-earnings ratio of -7.31 and a beta of -14.16. Aquinox Pharmaceuticals has a 12 month low of $10.02 and a 12 month high of $16.90.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its quarterly earnings data on Tuesday, May 8th. The company reported ($0.62) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.70) by $0.08. equities research analysts expect that Aquinox Pharmaceuticals will post -2.24 earnings per share for the current year.
In other news, Director Daniel J. Levitt sold 3,906 shares of the firm’s stock in a transaction that occurred on Monday, May 14th. The shares were sold at an average price of $12.67, for a total transaction of $49,489.02. Following the completion of the sale, the director now owns 3,906 shares in the company, valued at approximately $49,489.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 4.00% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in AQXP. D.A. Davidson & CO. increased its holdings in shares of Aquinox Pharmaceuticals by 42.8% during the 4th quarter. D.A. Davidson & CO. now owns 14,350 shares of the company’s stock worth $169,000 after buying an additional 4,300 shares during the last quarter. Eversept Partners LLC purchased a new position in shares of Aquinox Pharmaceuticals during the 4th quarter worth approximately $235,000. Emory University boosted its position in shares of Aquinox Pharmaceuticals by 38.3% during the 4th quarter. Emory University now owns 170,404 shares of the company’s stock worth $2,004,000 after purchasing an additional 47,154 shares during the period. University of Notre Dame DU Lac boosted its position in shares of Aquinox Pharmaceuticals by 32.0% during the 4th quarter. University of Notre Dame DU Lac now owns 251,091 shares of the company’s stock worth $2,953,000 after purchasing an additional 60,808 shares during the period. Finally, Stonepine Capital Management LLC purchased a new position in shares of Aquinox Pharmaceuticals during the 4th quarter worth approximately $476,000. Institutional investors and hedge funds own 91.11% of the company’s stock.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.